[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=5a2516e2c6be1defc81eb1de76eff67ca6f25de4c9e0e677dd15ccb06f30400b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736958660,
      "headline": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
      "id": 132408175,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=5a2516e2c6be1defc81eb1de76eff67ca6f25de4c9e0e677dd15ccb06f30400b"
    }
  },
  {
    "ts": null,
    "headline": "Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again",
    "summary": "Undervalued biotech company Regenxbio Inc. shows promise with cutting-edge gene therapy technology for AMD and MPS II. Click for this RGNX stock update.",
    "url": "https://finnhub.io/api/news?id=5b2cb3bd3b1443de0c48f8bb08624a17fbc787db04d6f86379b2f875e8ac616f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736954878,
      "headline": "Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again",
      "id": 132401300,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Undervalued biotech company Regenxbio Inc. shows promise with cutting-edge gene therapy technology for AMD and MPS II. Click for this RGNX stock update.",
      "url": "https://finnhub.io/api/news?id=5b2cb3bd3b1443de0c48f8bb08624a17fbc787db04d6f86379b2f875e8ac616f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)",
    "summary": "AbbVie Inc. (NYSE:ABBV) J.P.",
    "url": "https://finnhub.io/api/news?id=325184331ca2fe1bfc298e8bd401bf43729b0e5b2abfdc44224f7699b13b109a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736951283,
      "headline": "AbbVie Inc. (ABBV) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)",
      "id": 132401086,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. (NYSE:ABBV) J.P.",
      "url": "https://finnhub.io/api/news?id=325184331ca2fe1bfc298e8bd401bf43729b0e5b2abfdc44224f7699b13b109a"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Value Fund Q4 2024 Commentary",
    "summary": "Strategy outperformed its Russell 1000 Value benchmark during 4Q, as positive contributions from stock selection and sector allocation effects contributed to relative performance.",
    "url": "https://finnhub.io/api/news?id=16104d7a68c2939ee98b902963633ee224985f62212a98b4fd4a0b33be489f73",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736925600,
      "headline": "ClearBridge Value Fund Q4 2024 Commentary",
      "id": 132399220,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Strategy outperformed its Russell 1000 Value benchmark during 4Q, as positive contributions from stock selection and sector allocation effects contributed to relative performance.",
      "url": "https://finnhub.io/api/news?id=16104d7a68c2939ee98b902963633ee224985f62212a98b4fd4a0b33be489f73"
    }
  }
]